A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...